PurposeTo study the antiangiogenic effect of thalidomide.Patients and MethodsThe expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide.ResultsThalidomide markedly downregulates the genes in a dose-dependent fashion in active MMECs and KS cell line, but upregulates them or is ineffective in nonactive MMECs, MG(u)ECs, NHL-ECs, and in HUVECs. Secretion of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and hepatocyte growth factor also diminishes according to the dose in culture conditioned media (CM) of active MMECs and KS, whereas it does not change in the other CM.ConclusionInhibition by thalidomide is probably confined to the genes of active MMECs and KS. This would account for its higher efficacy in these diseases.

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma / Vacca, A; Scavelli, C; Montefusco, V; DI PIETRO, G; Neri, A; Mattioli, M; Bicciato, Silvio; Nico, B; Ribatti, D; Dammacco, F; Corradini, P.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 23:23(2005), pp. 5334-5346. [10.1200/JCO.2005.03.723]

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma

BICCIATO, Silvio;
2005

Abstract

PurposeTo study the antiangiogenic effect of thalidomide.Patients and MethodsThe expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide.ResultsThalidomide markedly downregulates the genes in a dose-dependent fashion in active MMECs and KS cell line, but upregulates them or is ineffective in nonactive MMECs, MG(u)ECs, NHL-ECs, and in HUVECs. Secretion of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and hepatocyte growth factor also diminishes according to the dose in culture conditioned media (CM) of active MMECs and KS, whereas it does not change in the other CM.ConclusionInhibition by thalidomide is probably confined to the genes of active MMECs and KS. This would account for its higher efficacy in these diseases.
2005
23
23
5334
5346
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma / Vacca, A; Scavelli, C; Montefusco, V; DI PIETRO, G; Neri, A; Mattioli, M; Bicciato, Silvio; Nico, B; Ribatti, D; Dammacco, F; Corradini, P.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 23:23(2005), pp. 5334-5346. [10.1200/JCO.2005.03.723]
Vacca, A; Scavelli, C; Montefusco, V; DI PIETRO, G; Neri, A; Mattioli, M; Bicciato, Silvio; Nico, B; Ribatti, D; Dammacco, F; Corradini, P.
File in questo prodotto:
File Dimensione Formato  
JCO1.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 369.45 kB
Formato Adobe PDF
369.45 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/421447
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 125
  • ???jsp.display-item.citation.isi??? 106
social impact